Daniell McSweeny, APRN
Family · Lancaster, OHNPI 1295352482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$621
- Astellas Pharma US Inc$473
- Currax Pharmaceuticals LLC$427
- Pfizer$304
- Amgen$276
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,60496%
- Education$2164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $1,334 |
| Novo Nordisk | 36 | $621 |
| Astellas Pharma US Inc | 21 | $473 |
| Currax Pharmaceuticals LLC | 61 | $427 |
| Pfizer | 20 | $304 |
| Amgen | 17 | $276 |
| Mayne Pharma Commercial LLC | 14 | $238 |
| Sumitomo Pharma America, Inc. | 11 | $182 |
| Myriad Women's Health, Inc. | 2 | $180 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $161 |
| Therapeuticsmd, Inc. | 10 | $154 |
| Corcept Therapeutics | 7 | $141 |
| Aspira Women's Health Inc | 2 | $112 |
| Lilly USA, LLC | 7 | $109 |
| IBSA Pharma Inc. | 6 | $91 |
| Exeltis, USA Inc. | 6 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Nestle Healthcare Nutrition Inc. | 6 | $86 |
| Mylan Pharmaceuticals Inc. | 4 | $83 |
| Shield Therapeutics Inc | 5 | $81 |
| Biohaven Pharmaceuticals, Inc. | 5 | $80 |
| Exact Sciences | 4 | $73 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
| Hologic Sales And Service, LLC | 3 | $57 |
| Millicent US Inc | 3 | $57 |
| Myovant Sciences Inc. | 3 | $55 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Organon | 3 | $35 |
| Alfasigma USA, Inc. | 2 | $33 |
| Acella Pharmaceuticals, LLC | 2 | $29 |
| Lupin Inc. | 2 | $27 |
| Bayer | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $16 |
How this compares
$5,821 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 14 | $17,744 |
| MounjaroTirzepatide | 14 | $14,391 |
| Estradiol | 45 | $3,424 |
| ProgesteroneProgesterone, Micronized | 29 | $1,151 |
| Clobetasol Propionate | 15 | $904 |
| Estradiol (Once Weekly)Estradiol | 15 | $848 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $182 | $17,74414 claims |
| Lilly USA, LLCMounjaro | $109 | $14,39114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Lancaster
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.